Preskorn Sheldon H
PRESKORN: Kansas University School of Medicine-Wichita, Wichita, KS.
J Psychiatr Pract. 2018 Jul;24(4):261-268. doi: 10.1097/PRA.0000000000000322.
This column begins a series exploring drug-drug interactions (DDIs) with a special emphasis on psychiatric medications. As explained in this column, this topic is important for multiple reasons. First, a large percentage of the population is receiving psychiatric medications. Second, these patients are likely to be on multiple medications which means that they are at risk for an adverse DDI. Third, DDIs may occur but not be recognized even though they have significant health care consequences for the patient. Fourth, these consequences can range from a catastrophic outcome to more everyday clinical problems involving a myriad of presentations as enumerated in this column. Also discussed in this column is the fact that all drugs, including psychiatric medications, interact on the basis of their pharmacodynamics and pharmacokinetics rather than their therapeutic use. Therefore, psychiatric medications may interact with medications prescribed for nonpsychiatric reasons as well as with other psychiatric medications. Tables are included that explain reasons for multiple medication use and principles to follow to minimize the risk of adverse DDIs.
本专栏将开启一个系列，探讨药物相互作用（DDIs），特别关注精神科药物。正如本专栏所解释的，这个话题之所以重要有多个原因。首先，很大一部分人口正在服用精神科药物。其次，这些患者可能同时服用多种药物，这意味着他们有发生不良药物相互作用的风险。第三，药物相互作用可能发生，但即使对患者有重大的医疗后果也可能未被识别。第四，这些后果从灾难性后果到涉及本专栏列举的无数表现的日常临床问题不等。本专栏还讨论了一个事实，即所有药物，包括精神科药物，都是基于其药效学和药代动力学相互作用，而不是基于其治疗用途。因此，精神科药物可能与因非精神科原因开具的药物以及其他精神科药物发生相互作用。文中还列出了表格，解释了使用多种药物的原因以及为将不良药物相互作用风险降至最低而应遵循的原则。
